Russell Investments Group Ltd. Has $867,000 Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN)

Russell Investments Group Ltd. increased its holdings in shares of UroGen Pharma Ltd. (NASDAQ:URGN) by 67.5% during the 2nd quarter, Holdings Channel reports. The institutional investor owned 56,876 shares of the company’s stock after acquiring an additional 22,923 shares during the quarter. Russell Investments Group Ltd.’s holdings in UroGen Pharma were worth $867,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of the stock. BNP Paribas Arbitrage SA lifted its position in shares of UroGen Pharma by 17.4% in the 1st quarter. BNP Paribas Arbitrage SA now owns 4,439 shares of the company’s stock worth $86,000 after purchasing an additional 657 shares during the period. Public Employees Retirement System of Ohio lifted its position in shares of UroGen Pharma by 21.1% in the 1st quarter. Public Employees Retirement System of Ohio now owns 6,900 shares of the company’s stock worth $134,000 after purchasing an additional 1,200 shares during the period. Algert Global LLC acquired a new position in shares of UroGen Pharma in the 1st quarter worth approximately $227,000. Barclays PLC lifted its position in shares of UroGen Pharma by 89.7% in the 1st quarter. Barclays PLC now owns 20,068 shares of the company’s stock worth $392,000 after purchasing an additional 9,490 shares during the period. Finally, GSA Capital Partners LLP acquired a new position in shares of UroGen Pharma in the 1st quarter worth approximately $459,000.

Shares of NASDAQ URGN opened at $15.94 on Tuesday. UroGen Pharma Ltd. has a 52-week low of $14.19 and a 52-week high of $28.20. The company’s 50 day moving average price is $15.81 and its 200-day moving average price is $17.28. The company has a market capitalization of $333.15 million, a P/E ratio of -3.17 and a beta of 1.22.

UroGen Pharma (NASDAQ:URGN) last released its earnings results on Wednesday, August 4th. The company reported ($1.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.10) by ($0.07). UroGen Pharma had a negative net margin of 349.05% and a negative return on equity of 127.56%. The company had revenue of $13.03 million for the quarter, compared to analyst estimates of $13.00 million. On average, sell-side analysts expect that UroGen Pharma Ltd. will post -4.9 earnings per share for the current year.

Separately, Zacks Investment Research downgraded shares of UroGen Pharma from a “hold” rating to a “sell” rating in a research report on Tuesday, July 20th.

UroGen Pharma Company Profile

UroGen Pharma Ltd. is a biopharmaceutical company dedicated to building novel solutions that treat specialty cancers and urologic diseases. It has developed RTGel reverse-thermal hydrogel, a proprietary sustained release, hydrogel-based platform technology that has the potential to improve therapeutic profiles of existing drugs.

Further Reading: Initial Coin Offering (ICO)

Want to see what other hedge funds are holding URGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for UroGen Pharma Ltd. (NASDAQ:URGN).

Institutional Ownership by Quarter for UroGen Pharma (NASDAQ:URGN)

Receive News & Ratings for UroGen Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for UroGen Pharma and related companies with MarketBeat.com's FREE daily email newsletter.